Abstract 177P
Background
Chemotherapy with Taxanes is often the preferred clinical treatment for breast cancer patients. Unfortunately, these agents become increasingly ineffective during treatment. Pro-tumoral M2 tumor-associated macrophages (TAMs) are the most abundant immune cells in the breast tumor microenvironment. In a first-in-human study (NCT00358163, NCT00731861), Vatalanib (PTK787/ZK) was well tolerated alone or in combination with paclitaxel. Here, we explored the pre-clinical efficacy of combination of Vatalanib and paclitaxel in TAM-induced chemoresistance in breast cancer.
Methods
We reported translational analysis of expression of BIRC5 and its correlation with Overall Survival (OS) in breast cancer patients. Western blotting, immunofluorescence imaging, and Real-time PCR analysis were used to determine survivin (BIRC5), pVEGFR2 and STAT3 in vitro. 4T1 cells and RAW 264.7 cells were injected in BALB/c mice to generate syngeneic chemoresistant breast tumor model in vivo.
Results
We measured survivin (BIRC5) upregulation in breast tumor (n=288) as compared to normal breast tissue (n=211) using TCGA datasets. Further, retrospective study confirmed that an increase in BIRC5 expression decreases Overall Survival (OS) in breast cancer. Using the invitro co-culture system, we validated that the macrophage secreted VEGF-A contributes to chemoresistance against paclitaxel. Mechanistically, VEGFA, by binding to VEGFR2, activated the transcription factor STAT3 leading to increased expression of anti-apoptotic protein survivin in breast cancer cells. Therapeutically, the TAM-induced STAT3/survivin signaling could be abrogated by Vatalanib thereby reversing the chemoresistance. The data shows that the combination of paclitaxel with Vatalanib exhibit reduced M2-TAMs, indicating that the combination effectively altered tumor microenvironment in the in vivo 4T1 breast tumor model.
Conclusions
Together, our study revealed the role of TAMs in conferring paclitaxel resistance in breast cancer. Combinatorial VEGFR2 blockade and paclitaxel chemotherapy decreased TAM population and showed better prognostic outcomes in breast cancer.
Legal entity responsible for the study
B. Deswal, S. Kapoor.
Funding
Department of Biotechnology, Government of India; Department of Science and Technology, Government of India.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
126P - Evaluation of Myeloid Targeting Agents, PY159 and PY314, in Two Dose Expansion Phase 1b Trials in Platinum-Resistant Ovarian Cancer
Presenter: Oladapo Yeku
Session: Poster Display
116TiP - Randomized, open-label, phase II study of botensilimab (BOT) alone and in combination with balstilimab (BAL) versus standard-of-care in patients with refractory metastatic colorectal cancer
Presenter: Eric Van Cutsem
Session: Poster Display
127P - REGN5668 (MUC16xCD28 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase 1 dose-escalation study
Presenter: Ira Winer
Session: Poster Display
128P - A phase I dose escalation and expansion trial of LYT-200, a Galectin-9 antibody +/- tislelizumab
Presenter: Gerald Falchook
Session: Poster Display
129P - Naxitamab efficacy in patients with refractory/relapsed high-risk neuroblastoma and bone metastases as assessed by Curie score
Presenter: Brian Kushner
Session: Poster Display
131P - Safety and clinical efficacy of Roginolisib (IOA-244), the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3K_)
Presenter: Anna Di Giacomo
Session: Poster Display
132P - A phase I clinical trial of QLS31905 in advanced solid tumors
Presenter: Yakun Wang
Session: Poster Display
133P - Phase 1/2 study of XTX101, a masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors
Presenter: Diwakar Davar
Session: Poster Display
134P - A Phase 1 Study Exploring the Safety and Tolerability of the Small Molecule PD-L1 Inhibitor INCB099318 in Select Advanced Solid Tumors
Presenter: David Pinato
Session: Poster Display
135P - Isunakinra as Monotherapy and Combined with Nivolumab for Treatment Resistant Advanced Solid Tumours: Exploratory Effect Data, Tolerability, and Pharmacokinetics from a Dose Escalation Trial
Presenter: Carlos Becerra
Session: Poster Display